Spleen volume reduction and transfusion independence with momelotinib versus ruxolitinib and associated overall survival with momelotinib in JAK inhibitor-naive patients with myelofibrosis and anemia: Subgroup analyses of SIMPLIFY-1

Authors

• Francesca Palandri, Universitaria di Bologna
• Stephen T Oh, Washington University School of Medicine in St. Louis
• et al.

Journal

Clinical Lymphoma Myeloma and Leukemia

Publication Date

5-1-2026

Volume

26

Issue

5

First Page

297

Last Page

308.e1

Document Type

Open Access Publication

DOI

10.1016/j.clml.2026.02.004

Rights and Permissions

Palandri F, Schaap NPM, Rey J, von Bubnoff N, Reiter A, Hernandez-Boluda JC, Devos T, Nilsson L, Psaila B, McLornan DP, Strouse B, Zhang S, Patel B, Lim J, Patnaik D, Oh ST. Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1. Clin Lymphoma Myeloma Leuk. 2026 May;26(5):297-308.e1. doi: 10.1016/j.clml.2026.02.004. © 2026 The Author(s). Published by Elsevier Inc.This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/)

Recommended Citation

Palandri, Francesca; Oh, Stephen T; and et al., "Spleen volume reduction and transfusion independence with momelotinib versus ruxolitinib and associated overall survival with momelotinib in JAK inhibitor-naive patients with myelofibrosis and anemia: Subgroup analyses of SIMPLIFY-1." Clinical Lymphoma Myeloma and Leukemia. 26, 5. 297 - 308.e1. (2026).
https://digitalcommons.wustl.edu/oa_4/7454

Department

ICTS (Institute of Clinical and Translational Sciences)